DNA Methylation Market Size, Share & Trends Analysis Report By Technology (PCR, Microarray, Sequencing), By Application (Gene Therapy, Diagnostics), By Product, By End Use, By Region, And Segment Forecasts, 2024 - 2030

DNA Methylation Market Size & Trends

The global DNA methylation market size was valued at USD 1.47 billion in 2023. It is expected to expand at a CAGR of 14.1% from 2024 to 2030. The rising number of cancer cases worldwide continues to be the main factor driving its projected expansion. For instance, as per the cancer statistics presented by the National Cancer Institute, the rate of new cancer cases is approximately 440.5 cases per 100,000 men and women per year.

Furthermore, the continual decrease in treatment costs alongside the simplification of product approvals continues to drive growth consistently. Moreover, substantial backing for research and development endeavors through direct financial support remains instrumental in creating fresh possibilities for expansion. DNA methylation continues to show promise in advancing research in key areas of treating chronic diseases. For instance, Base Genomics, an epigenetics company, has recently come out of hiding with a team of top scientists and $11 million USD (£9 million GBP) in seed funding to further advance its DNA methylation technology.

The method of analyzing DNA methylation assists scientists in obtaining important information about gene regulation and identifying potential biomarkers. Unusual DNA methylation has been linked to various disease processes, including obesity, cancer, and other conditions. It also offers potential for use in agronomic research in examining reactions to extreme temperatures, drought, and other environmental shifts.

Moreover, different high-throughput methods such as microarrays and next-generation sequencing (NGS) have made it easier to conduct research on genome-wide methylation profiling. These technologies provide methods for comprehending the importance of DNA methylation, offering understanding of the functional impacts of variation.

Technology Insights

Microarray segment dominated the market and accounted for a share of 41.29% in 2023. Bisulfite genomic sequencing is regarded as a technology of high standard. Scientists have used whole-genome bisulfite sequencing to investigate the epigenetic patterns of immune-related illnesses triggered by tobacco consumption. The advancement of this technology in research investigations to comprehend the negative impacts of smoking and its connection to diseases indicates potential for more growth in the field.

Sequencing segment is expected to grow significantly with a CAGR of 14.5% during the forecast period due to the quick evolution of technologies that provide affordable, precise, and speedy outcomes. Bisulfite genomic sequencing is widely regarded as the most reliable technology available. Scientists have utilized whole-genome bisulfite sequencing to investigate the epigenetic profile of immune-related diseases triggered by smoking. The expansion of this technology in research endeavors to explore the negative impacts of smoking and its connection to diseases offers additional growth potential in the field.

Product Insights

Enzymes segment accounted for the largest market revenue share of 35.9% in 2023 due to the increasing demand for protein-modifying and enzymes in the DNA methylation market. These are commonly utilized in agrigenomic research, genomic research, and genome-wide analysis. Enzymes are still widely utilized in DNA methylation reactions for sequencing analysis, including Illumina sequencing and pyrosequencing.

Instruments & software segment is expected to grow significantly with a CAGR of 13.9% during the forecast period. The growing utilization of NGS technologies has transformed the examination of DNA methylation, allowing for efficient and cost-friendly assessment of epigenetic patterns. Microarray technologies provide a flexible and accurate method for examining DNA methylation, especially for focused investigations. Increased understanding of the significance of epigenetics in biological processes has resulted in higher levels of research and a need for DNA methylation analysis tools.

Application Insights

Clinical research segment accounted for the largest market revenue share of 40.3% in 2023 due to the growing number of clinical trials for various diseases worldwide. Moreover, higher investment in research and development, along with a rising need for potential biomarkers, offer additional prospects for growth.The different phases consist of evaluating predisposition and risk, early detection screening, and providing individualized care for chronic and recurring illnesses. Hence, the identification of disease-related biomarkers holds great promise and revolutionize precision medicine.

The diagnostic segment is expected to register the fastest CAGR during the forecast period. DNA methylation profiling is an emerging tool that promises to increase the accuracy of pathological diagnosis. For instance, Histomorphology has been a cornerstone of cancer detection in anatomic pathology.Despite being a new arrival, methylation profiling can serve as a cancer diagnostic tool for all types of tumors.

End Use Insights

Pharmaceutical & biotechnology companies segment accounted for the largest market revenue share of 46.3% in 2023. The main factor contributing to the growth in molecular biology and genomics is the rising use of DNA methylation. In addition, the growing utilization of advanced technologies such as NGS by important market participants is also creating fresh avenues for expansion.

The Research and academia segment is expected to register the fastest CAGR of 15.0% during the forecast period. This growth can be attributed to the rise in research and development activities within the field of epigenetics. This, along with growing governmental financial aid, continues to be encouraging factors for economic expansion.

Regional Insights

North America dominated the DNA methylation market in 2023. The reason for this can be traced back to the extensive network of manufacturing and research and development centers, along with the rise in product introductions and approvals. In addition, the increasing request for protein expression systems has also played a major role in the regional expansion.

U.S. DNA Methylation Market Trends

The U.S DNA methylation market accounted for the market share of 71.8% in 2023 due to the growing use of DNA methylation detection technology as epigenetic biomarkers, increasing partnerships among academic institutions, and the emergence of more startups in the biotechnology and pharmaceutical sector.

Europe DNA Methylation Market Trends

Europe is estimated with 30.9% market share in 2023 with a CAGR of 13.5% in the period from 2024 to 2030. Due to the growing utilization of individualized medicine methods and expanded support for genetic research projects In addition, the growth in revenue of the Europe DNA methylation market is being driven by the rising adoption of the technique in oncology and epigenetic research laboratories. Increased interest in DNA methylation in next-generation sequencing and genome-wide analyses has resulted in a higher utilization of this method. Some factors are anticipated to fuel revenue growth in the European market.

UK DNA methylation market is expected to grow rapidly in the coming years. UK universities and research centers have been actively engaged in investigating the impact of DNA methylation on different biological processes and diseases. This has caused a rise in the need for tools for analyzing DNA methylation. The UK government has allocated substantial funding for research endeavors focused on epigenetics, specifically in the realm of DNA methylation. This assistance has spurred creativity and expansion within the industry.

Asia Pacific DNA Methylation Market Trends

The Asia Pacific region is anticipated witness significant growth in the DNA Methylation Market in the forecast period, supported by various government initiatives. In addition, the increasing attention from international companies on the developing markets of Asia Pacific continues to be a positive factor for growth. For instance, In August 2022, the Chinese government granted Oncgnostics GmbH approval to distribute its GynTect test to medical professionals and individuals. This marks the initial approved methylation test in China for triaging cervical cancer cases.

China DNA methylation market held a substantial market share in 2023. The increased use of NGS technologies has allowed for efficient and affordable DNA methylation analysis, fueling the expansion of the market. Microarray techniques provide a flexible and accurate method for researching DNA methylation, especially for focused investigations. The Chinese government's funding in healthcare facilities and services is establishing a conducive atmosphere for the expansion of the DNA methylation market.

Key DNA Methylation Market Company Insights

Some key companies in the DNA methylation market include New England Biolabs, Sysmex Corporation, Abcam Limited, and others.Major industry players in the DNA methylation sector are implementing various strategies such as forming partnerships, collaborations, and expanding into new geographical areas.  

• F. Hoffmann-La Roche Ltd offers in-vitro diagnostics and medications for cancer and transplantation. The Company focuses on producing drugs for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology.

• Diagenode Diagnostics S.A. is developer of a technology platform dedicated to providing services for epigenetics research, biological sample preparation, and diagnostics tests. The company's cutting-edge technology platform provides advanced Bioruptor shearing and IP-Star automation instruments, reagent kits, and high-quality antibodies to simplify DNA methylation, ChIP, and ChIP-seq processes, allowing customers access to top-tier products.

Recent Developments

• In May 2024, QIAGEN announced the launch of its QIAseq Multimodal DNA/RNA Library Kit. The new kit enables seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS), as well as downstream target enrichment based on hybrid-capture from a single sample.

• In April 2024, NEB has announced the launch of the Monarch Mag Viral DNA/RNA Extraction Kit. This kit boosts the retrieval of small quantities of viral DNA to allow for very precise detection. The kit efficiently and consistently extracts viral RNA and DNA using a magnetic bead process, allowing for easy automation at a larger scale.

• June 2024, QIAGEN launched 35 new wet-lab tested digital PCR Microbial DNA detection assays for the use in its QIAcuity dPCR platform. The launch is expected to help the company in expanding in the field of in microbial research. These tests focus majorly on various pathogens causing tropical diseases, urinary tract infections (UTIs), and sexually transmitted infections (STIs).

• May 2024, Exact Sciences Corp., a company in cancer screening and diagnostic tests, is set to showcase 10 abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois from May 31 to June 4, 2024. Presentations is expected to provide new information validating the predictive and prognostic significance of the Oncotype DX Breast Recurrence Score test in a diverse range of racially and ethnically diverse patients.

DNA Methylation Market Report Scope

Global DNA Methylation Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global DNA Methylation market report based on technology, product, application, end use, and region:

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Polymerase Chain Reaction (PCR)

  • Microarray

  • Sequencing

  • Others

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Consumables

  • Kits & Reagents

  • Enzymes

  • Instruments & Software

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Gene Therapy

  • Clinical Research

  • Diagnostics

  • Others

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital & Diagnostics Laboratories

  • Pharmaceutical & Biotechnology Companies

  • Research & Academia

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait